|
| Anadrol 50 oxymetholone : |
Anadrol 50 oxymetholone is the U.S. brand name for oxymetholone, a very potent oral androgen. Since oxymetholone is quite reliable in its ability to increase red blood cell production, it showed great promise in treating cases of severe anemia. It turned out to be well suited for this purpose, and was popular for quite some time.
Anadrol 50 oxymetholone drug is shown to have a much more direct effect on the red blood cell count, without the side effects of a strong androgen. Anadrol 50 is considered by many to be the most powerful steroid available, with results of this compound being extremely dramatic. A steroid novice experimenting with oxymetholone is likely to gain 20 to 30 pounds of massive bulk, and it can often be accomplished in less than 6 weeks, with only 50-100mg a day.
Oxymetholone is a derivative of dihydrotestosterone, which gives it a structure that cannot be aromatized. As such, many have speculated as to what makes this hormone so troublesome in terms of estrogenic side effects. However we do find medical studies looking at this possibility. One such tested the progestational activity of various steroids including nandrolone, norethandrolone, methandrostenolone, testosterone and oxymetholone.
Anadrol 50 oxymetholone is also a very potent androgen. This factor tends to produce many pronounced, unwanted androgenic side effects. Oily skin, acne and body/facial hair growth can be seen very quickly with this drug. Many individuals respond with severe acne, often requiring medication to keep it under control
|
Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.
By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome.
Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.
By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level.
The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight.
|
| Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure ReductionHUENENBERG, Switzerland--(BUSINESS WIRE)--Jul 2, 2009 - Alcon, Inc. (NYSE:ACL) announced today that it has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma. The company recently...


GSK Further Extends its Product Portfolio in the Middle East and North AfricaLONDON, July 2, 2009--GlaxoSmithKline plc (GSK) today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m). The...


Current Status of the Development Programs of New Indications and Formulations for Aricept for Enhancing Patient ValueTOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are...


Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity InvestmentFirst-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson &...


Bayer Files Patent Infringement Lawsuit Against TevaLEVERKUSEN, Germany, July 1, 2009 - Bayer Schering Pharma AG, Germany and Bayer HealthCare Pharmaceuticals Inc. together with Schering Corporation have filed a patent infringement lawsuit in the U.S. Federal Court in the District of Delaware against...


Charles River Announces RMS Succession Plan and Organizational Enhancements- Real H. Renaud to Retire by End of 2010 –
- Dr. Davide Molho Promoted to Corporate Senior Vice President –
- Restructures Preclinical Services Business and Realigns Global Sales Organization –
WILMINGTON, Mass.--(BUSINESS...


Pfizer Updates Chantix (varenicline) Labeling in the United StatesProvides Specific Instruction to Physicians and Patients About Quitting Smoking with CHANTIX
NEW YORK--(BUSINESS WIRE)--Jul 1, 2009 - Pfizer Inc announced that it has updated the U.S. product labeling for CHANTIX® (varenicline), a prescription aid...


Roche Launches Novel Program to Ease Tamiflu Access to Developing EconomiesTamiflu Reserves Program designed as a pandemic insurance policy for the world’s developing economies
BASEL, Switzerland, 1 July 2009-- Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The...


Eisai and Pfizer Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease- NICE Commit to Reviewing Existing Guidance 'As Soon As Possible'
LONDON, July 1/PRNewswire/ -- On June 11, the National Institute for Health and Clinical Excellence (NICE) announced that, following consultation with stakeholders on the economic...


Iressa (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in EuropeLONDON, July 1, 2009--AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer...


CombinatoRx and Neuromed Sign Merger Agreement-- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources –
- Conference Call Scheduled for Today at 8:30am ET -
CAMBRIDGE, Mass. & VANCOUVER,...


Maxygen Announces Joint Venture with Astellas to Develop Protein Pharmaceuticals-Maxygen to Contribute R&D Operations and Assets to Newly-Formed Joint Venture-
-Astellas to be Granted 3-Year Option to Acquire Joint Venture-
-Maxygen Plans Strategic Restructuring of Remaining Operations-
-Maxygen to Host Conference Call on...


Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S.
Upfront Payment of $110 Million; Potential Deal Value Over $500 Million
Acorda to Host Conference Call at 8:30 a.m. Eastern Time Today
CAMBRIDGE, Ma. & HAWTHORNE,...


Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal CancerNEW YORK--(BUSINESS WIRE)--Jun 30, 2009 - Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus...


Collegium Pharmaceutical Announces the Sale of AllerNaze to LupinCUMBERLAND, R.I.--(BUSINESS WIRE)--Jun 30, 2009 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that Lupin has acquired all worldwide rights to AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50...


UCB (BE) - UCB and Biogen Idec Discontinue Phase II Clinical Trial of CDP323Preliminary interim efficacy analysis showed no clinically relevant benefit for patients
BRUSSELS (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase...


BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger AgreementMerged Company Will Focus on LibiGel® in Phase III Clinical Studies for Female Sexual Dysfunction and Seek Future Opportunities for GVAX Immunotherapies
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 30, 2009 -...


Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott LaboratoriesHorsham, PA (June 29, 2009) – Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit.
“We are pleased that the jury has ruled in...


Sanofi-Aventis Presents New R&D Model Project to Boost Innovation?? Centered on Patient Needs
?? Networking and Openness toward outside sources to strengthen Creativity and Innovation
?? A flexible and entrepreneurial Approach to Research
PARIS, June 30, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY)...


UCB Brings Neupro Back to All Patients in Europe
European Commission lifts the treatment restrictions for Neupro®
Neupro® can be prescribed for all patients in accordance with the approved indications
Neupro® available again to all patients with Parkinson's...


Christian Lajoux Appointed President for sanofi-aventis in FrancePARIS, June 29 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that Christian Lajoux is appointed President for sanofi-aventis in France. He was previously President and General Manager of Pharmaceutical Operations in...


ChemGenex to Seek Voluntary De-Listing From NASDAQ and to Restructure Board to Reflect Compliance NeedsMELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 29, 2009 - ChemGenex Pharmaceuticals Limited (ASX:CXS) advises that a decision has been taken by the Board to seek a voluntary de-listing from the NASDAQ Capital Market...


Simponi (Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisSmartJect™ Autoinjector
Horsham, PA and Kenilworth, NJ (June 25, 2009) – Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the...


Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related TargetsLicense Agreement with Celera Corporation on five cancer target molecules
Berlin, June 29, 2009 – Bayer Schering Pharma AG, Germany, has entered into an exclusive license agreement with Celera Corporation, California, USA, providing Bayer...


A Side Effect of Michael Jackson’s Tragic Death – Consumer Health EducationDrugs.com reported a massive 20,900% increase (yes, you read that correctly – twenty thousand, nine hundred percent) in interest for information on the prescription medication Demerol – allegedly prescribed for the legendary entertainer Michael...


Jerini AG (DE) - Ad hoc: Jerini AG to Wind Down its Preclinical ProgramsBerlin, June 26, 2009 - Jerini AG has decided to end all negotiations regarding the transfer of assets associated with Jerini AG's preclinical programs and to terminate the employees associated with these programs. The decision was taken following...


Sanofi-aventis Stands Behind the Safety of LantusBRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no...


Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEONATICK, Mass., June 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer (CEO) Jim Tobin will retire from the Company, and that its board of directors has appointed Ray...


Novo Nordisk Reaches Settlement With the Danish Authorities Regarding Oil-for-Food ActivitiesCOPENHAGEN, June 26, 2009--Novo Nordisk announced today that it has reached a settlement with the Danish Public Prosecutor for Serious Economic Crime regarding the company’s sales to Iraq during 2000 to 2003 under the United Nations...


Announcement of Establishment of a Holding Company in the U.S.TOKYO, June 26, 2009--The Company announces that at its meeting held on June 26, the Board of Directors decided to establish a wholly-owned company (a holding company) in the United States in July this year as follows:
1. Purposes and an outline of...


CHMP Issue OpinionsLONDON, June 25, 2009--The Committee for Medicinal Products for Human Use issued a number of opinions today. Summaries and links to the opinions and company statements regarding the opinions are below.
Committee For Medicinal...


Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial PositionDETROIT, June 26 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD), in an effort to update our shareholders, is providing additional information in regards to our financial position in light of the recent FDA...


U.S. Marshals Seize Drug Products Manufactured by Caraco Pharmaceutical Laboratories Ltd.FDA acts to prevent repeated drug quality problems
ROCKVILLE, Md., June 25, 2009--U.S. Marshals, at the request of the Food and Drug Administration, today seized drug products manufactured by Caraco Pharmaceutical Laboratories Ltd. (Caraco), at the...


ONGLYZA (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 DiabetesPARIS & LONDON--(BUSINESS WIRE)--Jun 25, 2009 - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive opinion from...


Uluru Discussions to Acquire York Pharma, plc Are Currently TerminatedADDISON, Texas, June 24 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales ("York") have been...


Sen. Grassley Seeks Information About Medical School Policies for Disclosure of Financial TiesWASHINGTON, June 24, 2009 --- Senator Chuck Grassley has asked 23 medical schools for information about their policies for conflicts of interest and requirements for disclosure of financial relationships between faculty members and the drug...


Novo Growth Equity Expands Team, and Will Invest Up to $200M Per YearIndustry veterans Scott A. Beardsley and Michael Shalmi join the team as senior partners
COPENHAGEN & BAGSVAERD, Denmark--(BUSINESS WIRE)--Jun 25, 2009 - Novo Growth Equity, an investment activity of Novo A/S, announced today that it has...


Baxter to Acquire Continuous Renal Replacement Therapy Business from Edwards LifesciencesDEERFIELD, Ill.--(BUSINESS WIRE)--Jun 23, 2009 - Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards'...


Teva Pharmaceuticals Issues Statement in Response to Federal Trade Commission Claims on Patent SettlementsNORTH WALES, Pa.--(BUSINESS WIRE)--Jun 24, 2009 - Teva Pharmaceuticals USA issues the following statement:
“Teva was astonished by the Federal Trade Commission's assertion yesterday that consumers would benefit from proposed...


Faes Farma and Pfizer Are Negotiating Semi Exclusive Licences for Bilastine in Certain CountriesBILBAO, Spain, June 22, 2009--Faes Farma is still in conversations with high level partners (Pfizer is the world leader) in order to complete the co-marketing agreements in Europe and in the big emergent markets.
Once the Registration Dossier has...


|
|
|
|